Recently, several semisynthetic penicillins have been introduced which have activity against gram-negative microorganisms (9) . In particular, efforts have been made to develop substituted penicillins active against strains of Pseudomonas. Alpha-carboxybenzyl penicillin (carbenicillin) was the first penicillin analogue to achieve clinical acceptance for treatment of infections due to Pseudomonas, and its activity has been characterized elsewhere (1, 6) . In addition, a number of investigators have reported parallel studies on alpha-sulfoaminopenicillins (4, 7) . Price et al. (7) reported that this latter group, characterized by the presence of a sulfoamino or modified sulfoamino group in the side chain, is markedly inhibitory to strains of Pseudomonas, Further, they are notably resistant against beta-lactamase destruction.
Prior investigators using BL-P1654, 6-[Ralpha-guanylureido)phenylacetamido]. penicillamic acid (5, 8, 10) , have reported a marked inhibitory activity of this penicillin against strains of Pseudomonas in addition to a resistance to the beta-lactamases produced by Pseudomonas strains. However, unlike the sulfoaminopenicillins, BL-P1654 retains a broad spectrum of antimicrobial activity against a large number of Enterobacteriaceae, This study was carried out to review the in vitro antimicrobial activity of this penicillin against Pseudomonas, and in particular to compare its bactericidal activity to that of carbenicillin. 
MATERIALS AND METHODS

RESULTS
Susceptibility studies. Table 1 shows the number of Pseudomonas strains susceptible to BL-P1654 at twofold increases in antibiotic concentration. Median MICs of BL-P1654 and carbenicillin were 12.5 and 100 ug/ml, respectively. The lack of bactericidal activity of BL-P1654 was often observed among strains of Pseudomonas, whereas strains of Enterobacteriaceae were killed frequently with levels of BL-P1654 near the respective MIC of each strain. The effect on bactericidal activity was not specific to the media, and similar bactericidal effects were seen when brain heart infusion and tryptic soy broth were utilized. 1967, an anti-Pseudomonas penicillin became a reality. However, the relative lack of potency of carbenicillin against Pseudomonas, which necessitates large, frequent doses and the emergence of resistant microorganisms or superinfections during therapy, has been a serious drawback.
Recently, several investigators have reviewed the antimicrobial activity of BL-P1654. Van Scoy and co-workers (10) reported that a concentration of 50 Ag of BL-P1654 per ml was inhibitory for 58% of strains of Pseudomonas. Of importance, they noted a 30-fold concentration difference between inhibitory and bactericidal concentrations for strains of Pseudomonas and Proteus. However, Price and his colleagues (8) found that 75% of their strains of Pseudomonas were inhibited by 8.0 ,g of BL-P1654 per ml, utilizing a nutrient agar assay system. The bactericidal activity of BL-P1654 against Pseudomonas was examined for only two strains in this latter study; however, they also noted a large disparity between MICs and MBCs. In addition, Price et al. demonstrated that resistance acquired to BL-P1654 by serial passage was cross-resistant with carbenicillin.
Bodey and co-workers (3) recently reviewed the pharmacology of BL-P1654 in humans.
Mean peak serum levels of 40.7 and 80.8,ug/ml were achieved after intravenous doses of 0.5 and 1.0 g, respectively. Fifty to sixty-five percent of each dose was excreted in the urine in 6 h, and serum concentrations after a dose of 1.0 g ranged from 6 to 23 ,g/ml at the end of a 4-h period. There was no evidence of accumulation of the drug over a 4-day period. However, the occurrence of renal tubular necrosis in dogs receiving large doses (100 to 400 mg/kg) was reported. High concentrations of drugs were achieved in the urine, despite a slightly slower renal excretion of BL-P1654 than most other penicillins. In addition, these investigators referred to an earlier study by Bodey and Stewart (5) in which 75% of Pseudomonas isolates were inhibited by BL-P1654 at concentrations of <12.5 ,ug/ml, and, in contrast to our findings, BL-P1654 failed to exhibit bactericidal activity in concentrations equal to its MIC in only 2% of their strains of Pseudomonas.
A nearly uniform lack of in vitro bactericidal activity against strains of Pseudomonas was noted in our study of BL-P1654. The fact that our study was carried out with recent isolates which could have acquired increased resistance may explain the divergent results. At present, these in vitro data suggest that this penicillin will have only limited use in infections due to Pseudomonas.
